Patients
death
CPS, DISEASE CHARACTERISTIC, ONCOLOGY
Among 847 patients enrolled in the global study,Demographics and baseline disease characteristics in the intention‐to‐treat population.
Abbreviations: CPS, combined positive score; ECOG PS, Eastern Cooperative Oncology Group performance status; IVRS, interactive voice‐response system; PD‐L1, programmed cell death ligand 1.In Japanese patients, the median time from randomization to the database cutoff date of June 15, 2021 (i.e., the same database cutoff date as the protocol‐specified final analysis for the global KEYNOTE‐355 population reported previouslyPatient disposition in the Japan subset. Median duration of treatment (for any component of study medication) in the pembrolizumab plus chemotherapy group and placebo plus chemotherapy group was 7.4 months (range, 0.3–44.3 months) and 7.1 months (range, 1.2 to 25.8 months), respectively. A summary of on‐study treatment exposure is provided in Table 